Safety and feasibility of granulocyte colony-stimulating factor (G-CSF) primed bone marrow (BM) using three days of G-CSF priming as stem cell source for pediatric allogeneic BM transplantation

There are limited data on the optimal dosing and schedule of G‐CSF priming prior to BM harvest. We evaluated the safety and efficacy of three days of G‐CSF of primed BM from related pediatric donors. Forty‐five children were treated. All donors received 5 μg/kg per day of G‐CSF as a single subcutane...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric transplantation 2014-09, Vol.18 (6), p.625-630
Main Authors: Hussein, Ayad Ahmed, Sharma, Shanta, Al-Zaben, Abdulhadi, Frangoul, Haydar
Format: Article
Language:English
Subjects:
Adolescent
Bone Marrow Transplantation
Child
Child, Preschool
Feasibility Studies
Female
Graft Survival
Granulocyte Colony-Stimulating Factor - administration & dosage
Granulocyte Colony-Stimulating Factor - pharmacology
granulocyte colony-stimulating factor primed bone marrow
Hematopoietic Stem Cell Mobilization - methods
Humans
Infant
Jordan
Male
pediatric
Transplantation Conditioning - methods
Transplantation, Homologous
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are limited data on the optimal dosing and schedule of G‐CSF priming prior to BM harvest. We evaluated the safety and efficacy of three days of G‐CSF of primed BM from related pediatric donors. Forty‐five children were treated. All donors received 5 μg/kg per day of G‐CSF as a single subcutaneous injection for three consecutive days prior to the BM harvest. The median age of the donors was seven yr (range, 0.8–18) and no donor experienced major adverse events related to G‐CSF administration. The median age for the recipients was five yr (0.3–16 yr). Thirty‐five patients had non‐malignant disorders. The median dose of nucleated (TNC) and CD34+, CD3 cells infused per recipient weight was 5.4 × 108/kg (range, 0.61–17), 4.7 × 106/kg (range, 1.6–19), and 43.8 × 106/kg (range, 1.8–95), respectively. All patients achieved neutrophil and platelets engraftment, at a median of 15 (range, 10–22) and 23 days (range, 13–111), respectively. At a median follow up of 60 months (range 12–100), the estimated five yr overall and EFS was 91% and 80%, respectively. Collection of BM following three days of G‐CSF priming from pediatric donors is safe and results in high TNC and CD34+ cell yield.
ISSN:1397-3142
1399-3046
DOI:10.1111/petr.12314